Silvant Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $280K | Hold |
9,981
| – | – | 0.01% | 181 |
|
|
2025
Q4 | $249K | Hold |
9,981
| – | – | 0.01% | 181 |
|
|
2025
Q3 | $254K | Hold |
9,981
| – | – | 0.01% | 181 |
|
|
2025
Q2 | $242K | Hold |
9,981
| – | – | 0.01% | 174 |
|
|
2025
Q1 | $253K | Hold |
9,981
| – | – | 0.01% | 172 |
|
|
2024
Q4 | $265K | Hold |
9,981
| – | – | 0.01% | 173 |
|
|
2024
Q3 | $289K | Hold |
9,981
| – | – | 0.01% | 167 |
|
|
2024
Q2 | $279K | Hold |
9,981
| – | – | 0.01% | 167 |
|
|
2024
Q1 | $277K | Hold |
9,981
| – | – | 0.01% | 171 |
|
|
2023
Q4 | $287K | Sell |
9,981
-78,532
| -89% | -$2.37M | 0.02% | 165 |
|
|
2023
Q3 | $2.94M | Hold |
88,513
| – | – | 0.18% | 80 |
|
|
2023
Q2 | $3.25M | Sell |
88,513
-14,143
| -14% | -$550K | 0.18% | 81 |
|
|
2023
Q1 | $4.19M | Hold |
102,656
| – | – | 0.27% | 66 |
|
|
2022
Q4 | $5.26M | Sell |
102,656
-230
| -0.2% | -$11K | 0.37% | 53 |
|
|
2022
Q3 | $4.5M | Sell |
102,886
-899
| -0.9% | -$43.7K | 0.31% | 58 |
|
|
2022
Q2 | $5.44M | Sell |
103,785
-1,411
| -1% | -$71.9K | 1.32% | 15 |
|
|
2022
Q1 | $5.45M | Sell |
105,196
-2,551
| -2% | -$132K | 1.04% | 16 |
|
|
2021
Q4 | $6.36M | Buy |
107,747
+28,390
| +36% | +$1.41M | 1.09% | 16 |
|
|
2021
Q3 | $3.41M | Sell |
79,357
-7,326
| -8% | -$325K | 0.61% | 40 |
|
|
2021
Q2 | $3.39M | Sell |
86,683
-2,293
| -3% | -$89.2K | 0.53% | 46 |
|
|
2021
Q1 | $3.22M | Hold |
88,976
| – | – | 0.55% | 45 |
|
|
2020
Q4 | $3.27M | Sell |
88,976
-5,329
| -6% | -$195K | 0.56% | 44 |
|
|
2020
Q3 | $3.28M | Sell |
94,305
-1,391
| -1% | -$48.8K | 0.61% | 36 |
|
|
2020
Q2 | $2.97M | Hold |
95,696
| – | – | 0.53% | 43 |
|
|
2020
Q1 | $2.96M | Hold |
95,696
| – | – | 0.65% | 41 |
|
|
2019
Q4 | $3.56M | Sell |
95,696
-597
| -0.6% | -$21.3K | 0.65% | 41 |
|
|
2019
Q3 | $3.28M | Sell |
96,293
-2,320
| -2% | -$84.4K | 0.65% | 45 |
|
|
2019
Q2 | $4.05M | Sell |
98,613
-930
| -0.9% | -$36.9K | 0.73% | 37 |
|
|
2019
Q1 | $4.01M | Sell |
99,543
-648
| -0.6% | -$26K | 0.72% | 39 |
|
|
2018
Q4 | $4.15M | Sell |
100,191
-92,061
| -48% | -$3.82M | 0.83% | 30 |
|
|
2018
Q3 | $8.04M | Sell |
192,252
-1,208
| -0.6% | -$46.5K | 0.99% | 21 |
|
|
2018
Q2 | $6.66M | Buy |
193,460
+26,691
| +16% | +$912K | 0.82% | 34 |
|
|
2018
Q1 | $5.62M | Buy |
+166,769
| New | +$5.73M | 0.72% | 51 |
|
Other funds holding PFE
VCM
VPM
Silvant Capital Management's PFE Position: Q1 2026 in Review
Silvant Capital Management held its Pfizer (PFE) position steady in Q1 2026 at 9,981 shares worth $280K. The position accounts for 0.01% of the portfolio, ranked #181.
Silvant Capital Management first reported a position in PFE in Q1 2018 and has held it in 33 quarters since. The position peaked at $8.04M in Q3 2018. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Silvant Capital Management held 9,981 shares of Pfizer worth $280K as of Q1 2026.
- Silvant Capital Management left its Pfizer share count unchanged in Q1 2026.
- Pfizer made up 0.01% of Silvant Capital Management's portfolio in Q1 2026, its #181 holding.
- Silvant Capital Management first reported a position in Pfizer in Q1 2018 and has held it in 33 quarters since.
- Silvant Capital Management's Pfizer position peaked at $8.04M in Q3 2018.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Silvant Capital Management's 13F filing for Q1 2026, filed 14 May 2026.